spacer
home > ebr > Spring 2006
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2006
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
Helen Tayton-Martin, EBR's Editor, casts an eye over the spring issue  
download pdf
bullet
BioFinance and Management
In offering a myriad of benefits to both universities and the public, spinouts are attracting government support, but long-term financing options are nevertheless a challenge. Dr Jonathan Savidge at UCL Biomedica considers approaches to funding, in Reeling in Returns from Biotech Spinouts  
download pdf
In Aiming for Success, Ian Dixon at PricewaterhouseCoopers LLP looks at the popularity of the AIM market, whose rate of new admissions now surpasses that of the LSE's main market  
download pdf
Funding remains a major concern for biotech, and investor attitudes are tempered with caution, but an air of optimism is emerging. Hanns-Peter Wiese at Global Life Science Ventures considers whether fortunes are shifting, in After the Hype: The Horizons for Biotech  
download pdf
bullet
BioBusiness Development
In Spinning Out of Constraints, Dr Catherine Beech at Cambridge Gateway Fund and Dr John Mihell at Warwick Ventures, define key factors that promote or limit the rate of spinout formation at UK universities  
download pdf
Joanne Pearson at PharmaVentures looks at the scientific, social and commercial advantages of R&D agreements, in Strength in Synergy  
download pdf
Alongside management, IP has been posited as a primary consideration in evaluating the prospects of life sciences technologies. Dana M Gordon at Foley Hoag LLP examines the importance of well-informed IP strategies in Proof of Purpose: The US Utility Requirement  
download pdf
Nicos Nicolaou at the Tanaka Business School, Imperial College London, explores the relationship between Institutional Structures and the Creation of University Spinouts  
download pdf
bullet
BioResearch and Innovation
Roger A Edwards, ScD, Donna Mayo, Sharon Els and Louis Kaczmarek of PA Consulting predict the potential success of emergency measures in Avian Flu А Pandemic Prevention  
download pdf
Drugs able to target multiple gene products and curb the formation of resistant tumour cells would extend the effectiveness of existing treatments, says Rudolf Fahrig of RESprotect GmbH, in Combating Chemoresistance А Chemogenomics Joins the Battleground  
download pdf
There are currently over 80 clinical trials of therapies directed against tumour blood vessels. Dietmar W Siemann at the Department of Radiation Oncology, University of Florida Shands Cancer Center, uncovers their potential, in Strength in Numbers: Pairing Vascular Anticancer Therapies  
download pdf
In Innovation for Regeneration, Dr Carola Dony at Scil Technology GmbH explores the history and future of therapies for cartilage defects  
download pdf
Cristina Serra at EVGN evaluates developments in the treatment of cardiovascular disease in When Body Plumbers turn into Molecular Experts  
download pdf
bullet
Discovery Technology
In Design and Optimise: The Art of RNA Interference, Maureen Young and Dmitriy Ovcharenko of Ambion Inc explore this powerful reverse genetics tool that has revolutionised the study of gene function  
download pdf
Debra Nickischer at Cellomics and Anja van Brabant Smith at Dharmacon detail the compatibility of RNAi and the HCS platform for the functional mapping of genes, in High Content Analysis Using Targeted RNAi-Mediated Gene Knockdown  
download pdf
In RNAi: The Silent System, Subrahmanyam Yerramilli and Eric Lader at QIAGEN Sciences, US, and Elizabeth Scanlan at QIAGEN GmbH, Germany, discuss the multiple applications of RNA interference  
download pdf
bullet
BioDevelopment and Regulatory
With the average cost of drug development now peaking at a massive $1.7 billion, the pressure on companies to generate revenue is greater than ever. Faiz Kermani at Chiltern looks at the specific hurdles involved and strategies to overcome them, in Risk Evasion: The Challenges Ahead  
download pdf
In The Human Factor, Neil Sullivan at Cord8 Ltd unravels complexities in the interpretation of the Human Tissue Act 2004, and asks whether it enhances previous legislation on the removal, storage and use of human organs and tissue  
download pdf
Philippe Stas, Dr Ivo van Walle and Dr Ignace Lasters at AlgoNomics tackle a thorn-in-the-side of biopharmaceutical development, in T-Cell Epitopes: Predicting Immunogenicity  
download pdf
Dr Graham Lappin and Professor Colin Garner at Xceleron Ltd explore Absolute Bioavailability Studies in Humans - the Merits of Accelerator Mass Spectrometry  
bullet
BioFormulation and Manufacturing
In Biopharmaceutical Sialylation, Dr Daryl L Fernandes at Ludger Ltd presents a guide to assembling a glycoprofiling scheme for characterisation of biopharmaceutical sialylation  
download pdf
Cold chain management goes under the spotlight in Trial Run by Dan Catizone of QuickSTAT  
download pdf
Dr Bettina Katterle, Kerstin Mяller and Melanie Dippel at NewLab BioQuality AG underline the importance of validated stability testing methods for biopharmaceuticals  
download pdf
In The Bioreactor Maze, Richard Dennett at Eden Biodesign clarifies the considerations to be made when selecting this key component of the production process  
download pdf
Claudia Petersen and Fran DeGrazio at West Pharmaceuticals investigate the problem of product/container interactions in Packaging Creation: Risk Mitigation  
download pdf
bullet
BioRegional
In Poised for Growth: Chicago's Solo Turn, Arun Bhatia at The University of Chicago Graduate School of Business provides an overview of the life sciences in the city hosting this year's BIO conference  
download pdf
bullet
Preview
A look ahead to SCIpharm 2006 - Where Science Meets Business  
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Kloeckner Pentaplast Announces Plans for New Lamination Facility


More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem which CMO should you pick when each is touting similar technical capabilities?
More info >>

Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement